Clinical trials: Breast Cancer, Male
Estrogen Receptor Positive, HER2/Neu Negative
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- NCT01928186
- Testing
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Advanced Malignancies
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
- Trial name
- NCT00948961
- Testing
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- Celldex Therapeutics
Stage IV Prostate Cancer, Stage IV Colon Cancer
Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer
This study is being done to find the effect of Dibenzyl Trisulphide (active ingredient in Guinea Hen Weed in combination in patients with stage four cancer of the breast, prostate, cervix and colon.
- Conditions
- Stage IV Prostate Cancer, Stage IV Colon Cancer, Stage IV Breast Cancer, Stage IV Cancer of the Cervix
- Trial name
- NCT04113096
- Testing
- Dibenzyl trisulphide capsules
- Where
- Jamaica
- Volunteers
- 104 people
- Sponsor
- The University of The West Indies
Prostate Cancer, Breast Cancer Female
Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26
The study should evaluate the biological distribution of 99mTc-RM26 in patients with prostate cancer and breast cancer. The primary objective are: 1.
- Trial name
- NCT04746638
- Testing
- whole body study and SPECT with 99mTc-RM26
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Prostate Cancer, Breast Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
This study will determine the best doses of docetaxel and lonafarnib when the two anti-cancer agents are used in combination. Patients with tumors for which treatment with docetaxel would be appropriate are eligible.
- Conditions
- Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer
- Trial name
- NCT00539968
- Testing
- Docetaxel plus lonafarnib
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Breast Cancer, Lung Cancer
Abraxane and Alimta in Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00470548
- Testing
- Abraxane, Alimta
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of California, Davis
Metastatic Breast Cancer, Metastatic Prostate Cancer
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
This is an open-label, first-in-human, exploratory Phase 0 study evaluating the safety and diagnostic imaging performance of the DOTA-STR-17126 theranostic pair in patients with advanced or metastatic breast or prostate cancer.
- Conditions
- Metastatic Breast Cancer, Metastatic Prostate Cancer, GRPR-Targeted Molecular Imaging, Theranostic Radiopharmaceuticals
- Trial name
- DOTA-STR-17126 (NCT07608848)
- Testing
- [177Lu]Lu-DOTA-STR-17126, [68Ga]Ga-DOTA-STR-17126
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Integrated Haematology and Oncology Network
Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
This phase I/Ib trial studies the side effects and best dose of Hu5F9-G4 (magrolimab) when given in combination with olaparib for the treatment of patients with breast or castrate-resistant prostate cancer that have spread from…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT05807126
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- 5 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Breast Carcinoma, Prostate Cancer Surgery
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease.
- Conditions
- Breast Carcinoma, Prostate Cancer Surgery, Thyroid Cancer, Parathyroid Adenomas
- Trial name
- NCT06835426
- Testing
- Single intravenous injection of the radiotracer, Imaging resected specimen using the high-resolution PET-CT specimen imager
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Algemeen Ziekenhuis Maria Middelares
Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
A first-in-human study using BDC-3042 as a single agent and in combination with cemiplimab in patients with advanced malignancies
- Conditions
- Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer
- Trial name
- NCT06052852
- Testing
- BDC-3042, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Breast Cancer, Colorectal Cancer
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00622674
- Testing
- cetuximab, bortezomib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Colon Cancer, Breast Cancer
Understanding the Value of Community Vital Signs in Primary Care
Social determinants of health (e.g. the income, education, and environment of patients) may exert greater influence on health outcomes than traditional clinical factors (e.g. lab results, diagnoses, and family history).
- Conditions
- Colon Cancer, Breast Cancer, Cervical Cancer, Prostate Cancer
- Trial name
- NCT02512835
- Testing
- Community vital signs
- Where
- 2 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Cancer
Advanced MRI Sequences for Radiation Therapy Treatment Planning
The purpose of this study is to determine if it would be helpful to use advanced MRI imaging techniques to take additional views of the tumor target for radiation treatment planning or treatment follow-up MRI.
- Trial name
- NCT02340715
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Medical College of Wisconsin
Breast Cancer
Study of Genes and Environment in Patients With Breast Cancer in the East Anglia Region of the United Kingdom
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00757211
- Testing
- polymorphism analysis, laboratory biomarker analysis, questionnaire administration
- Where
- United Kingdom
- Volunteers
- 6,000 people
- Sponsor
- Cancer Research UK
Advanced Solid Tumors Cancer
A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of…
- Trial name
- NCT03145909
- Testing
- ABBV-176
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 19 people
- Sponsor
- AbbVie
Breast Cancer, Gastrointestinal Cancer
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers
Sildenafil increases the therapeutic effect of doxorubicin used as treatment for cancers of solid tumors through both an increase in anti-tumor effects and protection from cardiac toxicity.
- Conditions
- Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Sarcoma
- Trial name
- NCT01375699
- Testing
- Doxorubicin, Sildenafil
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Virginia Commonwealth University
Breast Carcinoma, Malignant Digestive System Neoplasm
Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital
This study examines how the American College of Surgeons Geriatric Surgery Verification Program, also called the ACS GSV Program, is implemented at the James Cancer Hospital.
- Conditions
- Breast Carcinoma, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm
- Trial name
- NCT07606287
- Testing
- Serious Illness Conversation Program training, ACS Geriatric Surgery Verification Program Implementation
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
- Trial name
- NCT07145255
- Testing
- ADC
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- MBrace Therapeutics
Melanoma, Breast Cancer
Survival Monitoring in Russian Cancer Registries
This study aims to establish a holistic framework for continuous cancer survival surveillance in Russian regions with high-quality population-based cancer registry data.
- Conditions
- Melanoma, Breast Cancer, Oncology, Colon Cancer
- Trial name
- SURVIMON (NCT06043947)
- Where
- Russia
- Volunteers
- 100,000 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.